89Strontium in the management of painful sceletal metastases

Anticancer Research

Volumn 20, Issue 2 B, 2000, Pages 1109-1114

  Kälkner, Karl Mikael ^a   Westlin, Jan Erik ^a   Strang, Peter ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b VRINNEVI HOSPITAL   (Sweden)

Author keywords

Hormone refractory; Pain evaluation; Prostatic adenocarcinoma; Strontium 89 chloride; Therapy

Indexed keywords

CISPLATIN; DOXORUBICIN; STRONTIUM 89; STRONTIUM CHLORIDE; STRONTIUM;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; COST BENEFIT ANALYSIS; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; PROSTATE CARCINOMA; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; BONE TUMOR; METASTASIS; MORTALITY; OSTEOBLAST; PAIN; PALLIATIVE THERAPY; PATHOLOGY; PATHOPHYSIOLOGY; PROSTATE TUMOR; REVIEW; SURVIVAL;

BONE NEOPLASMS; FEMALE; HUMANS; MALE; OSTEOBLASTS; PAIN; PALLIATIVE CARE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; STRONTIUM RADIOISOTOPES; SURVIVAL ANALYSIS;

EID: 0033625686     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Pecher C: Biological investigations with radioactive calcium and strontium: preliminary report on the use of radioactive strontium in treatment of metastatic bone cancer. Pharmacol 11: 117-149, 1942.
2. Firusian N, Mellin P and Schmidt CG: Results of strontium-89 therapy in patients with carcinoma of the prostate and incurable pain from hone metastases: a preliminary report. J Urol 116: 764-768, 1976.
3. Schmidt CG and Firusian N: 89-Sr for the treatment of incurable pain in patients with neoplastic osseous infiltrations. Int J Clin Pharmacol 9: 199-205, 1974
4. Robinson RG, Blake GM and Preston DF, et al: Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographic 9: 271-281, 1989.
5. Blake GM, Zivanovic MA, McEwan AJ and Ackery DM: Sr-89 therapy: strontium kinetics in dissiminated carcinoma of the prostate. Eur J Nucl Med 12: 447-454, 1986.
6. Tennvall J, Darte L, Lundgren R and el Hassan AM: Palliation of multiple bone metastases from prostatic carcinoma with strontium-89. Acta Onco 7: 365-369, 1988.
7. Ben-Josef E, Lucas DR, Vasan S and Porter AT: Selective accumulation of strontium-89 in metastatic deposits in bone: Radiohistological correlation. Nucl Med Commun 16: 457-463, 1995.
8. Robinson RG, Preston DF, Schiefelbein M and Baxter KG: Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA 75: 420-424, 1995.
9. Lee CK, Aeppli DM, Unger J, Boudreau RJ and Levitt SH: Strontium-89 chloride (Metastron) for palliative treatment of bony metastases: the University of Minnesota experience. Am J ClinOncol 19: 102-107, 1996.
10. Laing AH, Ackery DM and Bayly RJ et al: Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. BrJ Radiol 64: 816-822, 1991.
11. Berna L, Carrio I, Alonso C, Ferre J, Estorch M and Torres G: Bone pain palliation with strontium-89 in breast cancer patients with bone metastases and refractory bone pain. Eur JNucl Med 22: 1101-1104, 1995.
12. Charron M, Brown M, Rowland P and Mirro J: Pain palliation with strontium-89 in children with metastatic disease. Med Pediatr Oncol 26: 393-396, 1996.
13. Silberstein E and Taylor Jr A: Procedure guidline for bone pain treatment: 1.0. J Nucl Med 7: 881-884, 1996.
14. Powsner RA, Zietman AL and Foss FM: Bone marrow supression after strontium-89 therapy and local radiation therapy in patients with diffuse marrow involvement. Clin Nucl Med 22: 147-150, 1997.
15. Ewan AJB, Porter AT, Venner PM and Amyotte G: An evaluation of safety and efficacy of treatment with strointium-89 in patients who have prevoiusly received wide field radiotherapy. Antib Immunoconj Radiopharm 3: 91-98, 1990.
16. Leong C, McKinzie MR, Coupland DB and Gascoyne RD: Disseminated intravascular coagulation in a patient with metastatic prostate cancer: fatal outcome following strontium- 89 therapy. J Nucl Med 5: 1662-1664, 1994.
17. Ridell AJ: Disseminated intravascular coagulation in metastatic prostate cancer. J Nucl Med 37: 401, 1996.
18. Lewington VJ, McEwan AJB and Ackery DM et al: A prospective, randomised double-blind study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastasic to bone. Eur J Cancel 7: 954-958, 1991.
19. Porter AT, McEwan AJB and Powe JE et al: Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistante metastati prostate cancer. Int J Radiat Oncol Biol Phys 25: 805-813, 1993.
20. Quilty PM, Kirk D and Bolger JJ et al: A comparison of the palliative effects of strontium-89 and extemal beam radiotherapy in metastatic cancer. Radiother Oncol 31: 33-40, 1994.
21. McEwan AJB, Amyotte GA, McGowan DG, MacGillivray JA and Poerter AT: A retrospective analysis of the cost effectiveness of treatment with Metastron in patients with prostate cancer metastatic to bone. Nucl Med Commun 15: 499-504, 1994.
22. Malmberg I, Persson U, Ask A, Tennvall J and Abrahamsson P-A: Painful bone metastases in hormone-refractory prosatae cancer Ecomonic costs of strontium-89 and/or external radiotherapy. Urol 50: 747-753, 1997.
23. Schmeler K and Bastin K: Strontium-89 for symptomatic metastatic prostate cancer to bone: Recommendations for hospice patients. Hosp J 11: 1-10, 1996.
24. Fossa SD, Paus E, Lochoff M, Melbye Backe S and Aas M: Strontium in bone metastases from hormone resistant prostate cancer: palliation effect and biochemical changes. Br J Cancer 66: 177-180, 1992.
25. Guerrieri P, Modoni S and Parisi S et al: Bone formation markers and pain palliation in bone metastases treated with strontium-89. Am J Clin Oncol 17: 77-79, 1994.
26. Papatheofanis FJ: Serum PICP as a bone formation marker in 89Sr and external beam radiotherapy of prostalic bony metastases. Br J Radiol 70: 594598, 1997.
27. Papatheofanis FJ: Quantitation of biochemical markers of bone resorbtion following strontium-89-chloride therapy for metastatic prostatic carcinoma. J Nucl Med 38: 1175-1179, 1997.
28. Mertens WC, Porter AT, Reid RH and Powe JE: Strontium-89 and low-dose infusion cisplatin for patients with hormone refractory prostate carcinoma metastatic to bone: a preliminary report. J Nucl Med 33: 1437-1443, 1992.
29. Sciuto R, Maini CL, Tofani A, Fiumara C, Scelsa MG and Broccatelli M: Radiosensitization with low-dose carboplatin enhances pain palliation in radioisotope therapy with strontium- 89. Nucl Med Commun 17: 799-804, 1996.
30. Delpassand ES, Jones D, Amato RJ, Ellerhorst J and Logothetis CJ: Strontium-89 combined with Doxorubicin in the treatment of patients with androgen-independent prostatecancer.Urol Oncol 2: 191-197, 1996.
31. Strang P and Qvarner H: Cancer-related pain and its influence on quality of life. Anticancer Res 10: 109-112, 1990.
32. Strang P: Emotional and social aspects of cancer pain. Acta Oncol 31: 323-326, 1992.
33. Strang P: Existential consequences of unrelieved cancer pain. Palliat Med 11: 299-305, 1997.
34. Fosså SD: Quality of life after palliative radiotherapy in patients with hormone-resistant prostate cancer: single institution experience. Br J Urology 74: 345-351, 1994.